On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.The Bank of Italy said that the economy may only grow by 0.5% this year, and the Bank of Italy said in a statement on Friday that the gross domestic product (GDP) will increase by 0.5% in 2024. If seasonal and calendar effects are not taken into account, this figure will increase to 0.7%, but it is lower than the government's estimate of 1% in the budget. In addition, GDP growth is expected to be 0.8% in 2025 and 1.1% in 2026. It is estimated that the unified average inflation rate in the EU will be 1.1% in 2024, which is the same as the estimated value in October, 1.5% in 2025 and 1.6% in 2025.Shanghai Shipping Exchange: The transportation demand of Persian Gulf routes remained high, and the market freight rate continued to rise this week. On December 13th, according to the news of Shanghai Shipping Exchange, this week, the export container transportation market in China was basically stable, and different routes were divided due to their different trends of supply and demand fundamentals, and the comprehensive index rose. On European routes, the growth of transportation demand is weak, the fundamentals of supply and demand lack further support, and the booking price in the spot market drops slightly. On the North American route, the transportation demand is generally stable, and the relationship between supply and demand is basically balanced. Major airlines push the freight rate up, and the spot market booking price rises sharply. On the Persian Gulf route, the transportation demand remained high, and the market freight rate continued to be supported by the local tension. This week, the market freight rate continued to rise. On the Australia-New Zealand route, the local demand for various materials showed signs of stabilization, the fundamentals of supply and demand improved, and the market freight rate stopped falling and rebounded. On the South American route, the transportation demand lacks the motivation for further growth, and the fundamentals of supply and demand weaken. This week, the spot market booking price dropped slightly.
Market News: Turkish anti-monopoly agency fined Google $75 million for advertising technology investigation.Guoyuan Securities: A special dividend plan was drawn up and announced by Guoyuan Securities. On December 13, 2024, the company held the 20th meeting of the 10th Board of Directors and the 11th meeting of the 10th Board of Supervisors, at which the Proposal on Special Dividend Plan was reviewed and approved. As of September 30, 2024, the accumulated undistributed profit of the company was 7.743 billion yuan, and the accumulated distributable profit of the parent company was 5.262 billion yuan. In order to enhance the investor's sense of gain and improve the investor's return level, the company has drawn up a special dividend plan: based on the existing total share capital of 4.364 billion shares, a cash dividend of 0.60 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 262 million yuan will be distributed. No bonus shares will be distributed, and capital will not be increased from the provident fund.During the battle of AI glasses, several new financings were under way in the field of AI glasses, among which Viture, which focuses on AR game scenes, and Even Realities, whose current product form is mainly a combination of AI and AR, have entered the late stage of the transaction, and their latest valuations both exceed 100 million US dollars. It is understood that Wang Huiwen, co-founder of Meituan, also recently invested in Viture. The old shareholders of this company founded in 2021 include Lanchi Venture Capital, BAI Capital and Zhenzhi Venture Capital. (latepost)
Li Yunze met with Timothy Geithner, Chairman of Huaping Investment Group, USA. Recently, Li Yunze, Party Secretary and Director of State Financial Supervision and Administration, met with TimothyF.Geithner, Chairman of Huaping Investment Group, USA and his party. The two sides exchanged views on the macroeconomic and financial situation, the development prospect of China's financial industry and Huaping's investment and development in China.Guoyuan Securities: A special dividend plan was drawn up and announced by Guoyuan Securities. On December 13, 2024, the company held the 20th meeting of the 10th Board of Directors and the 11th meeting of the 10th Board of Supervisors, at which the Proposal on Special Dividend Plan was reviewed and approved. As of September 30, 2024, the accumulated undistributed profit of the company was 7.743 billion yuan, and the accumulated distributable profit of the parent company was 5.262 billion yuan. In order to enhance the investor's sense of gain and improve the investor's return level, the company has drawn up a special dividend plan: based on the existing total share capital of 4.364 billion shares, a cash dividend of 0.60 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 262 million yuan will be distributed. No bonus shares will be distributed, and capital will not be increased from the provident fund.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.